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Cruchaga et al.1 recently showed that i) variants in the phospholipase D3 (PLD3) gene 39 
confer increased risk for the development of Alzheimer’s disease (AD), ii) PLD3 expression 40 
is decreased in sporadic AD patients and iii) the expression of PLD3 inversely correlates 41 
with the expression of Amyloid Precursor Protein (APP) and the production of Aβ peptides in 42 
vitro in cell lines. Altogether, the genetic and functional data led the authors to conclude that 43 
PLD3 loss-of-function confers an increased AD risk by affecting APP processing. Here we 44 
tested the relevance of Pld3 for APP processing in vivo in physiological conditions and in an 45 
AD-relevant model: Pld3 deficiency did not affect App metabolism or amyloid plaque burden. 46 
PLD3 is however localized in the lysosomal compartment and its loss-of-function alters its 47 
morphology, suggesting alternative functions for PLD3 in neurodegeneration. 48 
To test the effect of loss-of-function of PLD3 on brain physiology we acquired  the 49 
Pld3tm1e(EUCOMM)Wtsi mice (Pld3ko)2. These mice carry a trapping cassette with a splicing 50 
acceptor followed by a IRES:lacZ knocked-in in the Pld3 gene (Extended Data Fig. 1a). This 51 
insertion abrogates the expression of Pld3 and results in the expression of the β-52 
galactosidase reporter instead (Extended Data Fig. 1b). Western blot (WB) analysis (not 53 
shown) and X-gal staining showed that Pld3 is highly expressed in the pyramidal neurons of 54 
cortex and hippocampus; conversely, expression of the β-galactosidase was not detectable 55 
in the interneurons of the hippocampus nor in the glial cells of the corpus callosum 56 
(Extended Data Fig. 1d, 1d’, 1d’’ and 1d’’’). Morphometric analysis of the gross morphology 57 
of Pld3-deficient brains did not reveal any major abnormalities as compared to controls 58 
(Extended Data Fig. 1e and 1f). 59 
We investigated the effect of genetic deletion of Pld3 on App proteolysis. mRNA levels of 60 
App and different candidate genes, including Adam10, Bace1 and the γ-secretase complex 61 
subunits, are unchanged in Pld3-deficient cortices relative  to control brains (Extended Data 62 
Fig. 1c). Moreover, WB analysis shows that the expression of App full length (App FL), App 63 
C-terminal fragments (App CTF) and the ratio between App CTF and App FL are not 64 
affected by Pld3 deletion in neither the cortex nor the hippocampus (Fig. 1a, b and Extended 65 
Data Fig 1g,h). Finally, we assessed the levels of Aβ40 and Aβ42 in control and Pld3-66 
deficient mice by performing enzyme-linked immunosorbent assays (ELISA). Significantly, 67 
genetic deletion of Pld3 does not affect endogenous Aβ40 and Aβ42 generation in the cortex 68 
and hippocampus of 3-month old adult mice (Fig. 1b and Extended Data Fig. 1h). 69 
To establish the relevance of Pld3 in an AD-relevant model, we crossed Pld3ko mice with 70 
App knock-in mice (Appki) which have a humanized Aβ sequence in the endogenous App 71 
gene and contains three clinical relevant mutations to increase amyloidogenesis3. The model 72 
proposed by Cruchaga et al. predicts that loss of Pld3 function would increase amyloid 73 
burden. Consistent with the experiments above, Pld3 deletion did not alter the levels of App 74 
FL, App CTFs nor the App CTF/App FL ratio (Fig. 1c,d). The levels of Aβ40 and Aβ42 in tris-75 
buffered saline (TBS)-soluble and GuanidineHCl (Gu)–soluble fractions were not increased 76 
in Pld3ko;Appki compared to control mice (Fig. 1d and Extended Data Fig. 1i). Most 77 
importantly, Pld3 deletion did not have any effect on amyloid plaques burden (Fig. 2a,b) 78 
further confirming that Pld3 does not affect App metabolism in this AD-relevant mouse 79 
model. Future studies will be required to investigate the effect of Pld3 deletion in aged mice 80 
or in other AD-models (e.g. tau or ApoE models). 81 
We tried then to replicate the in vitro studies of Cruchaga et al. using transiently 82 
expressing PLD3 wild-type (WT), the catalytically inactive PLD3 K418R (KR)4 and the AD-83 
linked PLD3 V232M (VM) variant in HEK293T cells stably expressing human APP-WT. The 84 
results of these experiments turned out to be contradictory and highly variable. For instance 85 
and consistently with the work of Cruchaga et al., we observed a reduction in Aβ levels in 86 
cells expressing the PLD3 WT and mutant proteins (Extended Data Fig. 2a). In contrast to 87 
Cruchaga et al., APP FL were however not significantly affected by PLD3 expression 88 
(Extended Data Fig. 2b,c). Unexpectedly, the expression of AD-associated PLD3 VM 89 
variant, proposed by Cruchaga et al. as loss-of-function allele, also decreased Aβ 90 
generation. Notably, the overexpression of PLD3 in these experiments was >50 fold higher 91 
than the endogenous expression (not shown). We reasoned that the discrepancies in the 92 
results are likely explained by overexpression artefacts e.g. huge overexpression may lead 93 
to mislocalization of the protein-of-interest resulting in non-physiological interactions. 94 
Therefore, we further investigated the functional relevance of changes in PLD3 expression 95 
by utilizing milder overexpression conditions to more closely mimic a physiologically relevant 96 
context. We expressed decreasing amounts of PLD3 WT and the KR and VM mutants by 97 
Neon® electroporation in HEK293T cells to allow for a more uniform expression of the PLD3 98 
protein (about 20, 5 and 2 fold the endogenous level, Fig. 1u short and long exposures for 99 
PLD3). In this experimental paradigm, the expression of PLD3 WT and mutants does not 100 
reduce neither Aβ levels (Fig.1t) nor APP expression (Fig. 1u and 1f) confirming that the 101 
reported effects of Pld3 on APP reported in  Cruchaga et al. are artefacts due to huge 102 
overexpression of PLD3. 103 
Several AD-linked genes, that do not directly control APP processing, converge on the 104 
regulation of endosomal-autophagic-lysosomal function5, although the etiological role of 105 
endosomal-lysosomal impairment in AD is not completely understood6,7. Notably, defects in 106 
the endosomal-lysosomal system were found in AD brains8. Thus, we investigated the 107 
localization of Pld3 in early endosomes (stained with Early Endosome Antigen 1 (EEA1) 108 
marker) and in late endosomes and lysosomes (visualized with Lysosomal-associated 109 
membrane protein 1 (LAMP-1) marker). Pld3 was not enriched in early endosomes but was 110 
mostly localized to LAMP1 positive compartments (Extended Data Fig. 3a-d). Hence, we 111 
analysed by electron microscopy (EM) the ultrastucture of lysosomes in Pld3ko neurons. 112 
Primary and secondary lysosomes of Pld3 deficient CA1 neurons displayed an increase in 113 
density, size and in total area occupied (Extended data Fig. 3e-g). Moreover, several of 114 
these secondary lysosomes showed electron-transparent inclusions compatible with lipid 115 
droplets (16 out of 73 secondary lysosomes in Pld3ko vs 1 out of 22 in control brains). The 116 
identification of the precise mechanisms underpinning these alterations is out of the scope of 117 
the current study, nonetheless these results show that Pld3 is required to preserve the 118 
structure of lysosomes in vivo. 119 
In sum, our in vivo studies demonstrate that Pld3 is not relevant for App metabolism 120 
neither in wild type mice nor in a model of AD pathology. These data challenge the 121 
mechanistic model proposed by Cruchaga et al. and suggest a more complex role of PLD3 122 
in the etiology of AD. Our findings that PLD3 protein is localized in and affects the 123 
morphology of the lysosomal system indicate that PLD3 may be involved in the 124 
pathophysiology of AD by exacerbating the known impairments of endosomal-lysosomal 125 
systems5.  126 
 127 
  128 
References 129 
 130 
1. Cruchaga, C. et al. Rare coding variants in the phospholipase D3 gene confer risk for 131 
Alzheimer’s disease. Nature 505, 550–4 (2014). 132 
 133 
2. Skarnes, W. C. et al. A conditional knockout resource for the genome-wide study of 134 
mouse gene function. Nature 474, 337–342 (2011). 135 
 136 
3. Saito, T. et al. Single App knock-in mouse models of Alzheimer’s disease. Nat 137 
Neurosci 17, 661–663 (2014). 138 
 139 
4. Osisami, M., Ali, W. & Frohman, M. a. A role for phospholipase D3 in myotube 140 
formation. PLoS One 7, (2012). 141 
 142 
5. Nixon, R. a. The role of autophagy in neurodegenerative disease. Nat. Med. 19, 983–143 
997 (2013). 144 
 145 
6. Boland, B. et al. Macroautophagy is not directly involved in the metabolism of amyloid 146 
precursor protein. J. Biol. Chem. 285, 37415–37426 (2010). 147 
 148 
7. Lee, S., Sato, Y. & Nixon, R. A. Lysosomal Proteolysis Inhibition Selectively Disrupts 149 
Axonal Transport of Degradative Organelles and Causes an Alzheimer’s-Like Axonal 150 
Dystrophy. J. Neurosci. 31, 7817–7830 (2011). 151 
 152 
8. Cataldo,  a M., Hamilton, D. J., Barnett, J. L., Paskevich, P. a & Nixon, R. a. 153 
Properties of the endosomal-lysosomal system in the human central nervous system: 154 
disturbances mark most neurons in populations at risk to degenerate in Alzheimer’s 155 
disease. J. Neurosci. 16, 186–199 (1996). 156 
 157 
9. Morishima-Kawashima, M. et al. Effect of apolipoprotein E allele epsilon4 on the initial 158 
phase of amyloid beta-protein accumulation in the human brain. Am. J. Pathol. 157, 159 
2093–9 (2000). 160 
 161 
Authors contribution 162 
PF, conceived the project, planned the experiments, performed the experiments, 163 
analysed the results and wrote the manuscript; KH, performed in vitro experiments, 164 
and performed WB and ELISA analysis in vitro and in vivo (Fig. 1g-n and Fig. 1q-v); 165 
AMA, performed EM experiments and helped to analyse the data; CSF, performed 166 
and analysed qPCR experiments (Fig. 1b-c); TS, TCS, previously characterized and 167 
provided App knock-in mice; BDS, conceived and supervised the project, wrote the 168 
manuscript. All the authors revised the manuscript and helped with comments and 169 
feedback. 170 
Acknowledgements.  171 
cDNAs for human PLD3 WT and KR were kindly provided by Prof. Frohman. This work  172 
was supported by the European Research Council (ERC) ERC-2010-AG_268675 to BDS, 173 
the Fonds voor Wetenschappelijk Onderzoek (FWO), the KU Leuven and VIB, a 174 
Methusalem grant of the KU Leuven/Flemish Government to BDS. BDS is supported by the 175 
Bax-Vanluffelen Chair for Alzheimer’s Disease and “Opening the Future” of the Leuven 176 
Universiteit Fonds (LUF). Confocal microscope equipment was acquired through a Hercules 177 
Type 1 AKUL/09/037 to W. Annaert. Mouse experiments were supported by Inframouse 178 
(KU Leuven and VIB infrastructure). 179 
Material and methods 180 
 181 
HEK293T cells were transfect with TransIT-LT1® (Mirusbio, USA, product nos.MIR2300) 182 
or electroporated with Neon® (Invitrogen, Catalog Number MPK5000) according to 183 
manufacturer instructions. Pld3tm1e(EUCOMM)Wtsi mice (Pld3ko) were obtained from The 184 
European Mouse Mutant Archive-EMMA. AppNL-G-F/NL-G-F  knock-in mice (Appki) that carry the 185 
human Aβ sequence with triple Swedish, Arctic and Beyreuther/Iberian mutations were 186 
generated as described3. Detailed experimental procedures are provided in Supplemental 187 
Materials and Methods. 188 
Supplemental material and methods 189 
cDNA for PLD3 VM was generated by site directed mutagenesis and verified by 190 
sequencing.  191 
Cell lysates were prepared in STE with 1% Triton X-100. Densitometric quantification of 192 
WB were normalized for Actin levels. For the ELISA we collected cell supernatant and 193 
measured for Aβ by standard techniques. Data obtained were corrected for the levels of total 194 
intracellular protein measured by BCA. 195 
For quantitative PCR, RNA was retrotranscribed to cDNA with oligo dT primers using the 196 
SUperScript II Reverse transcriptase kit (Invitrogen). Real-time PCR was carried out using 197 
the LightCycler 480 SYBR Green I Master mix (Roche) on a LightCycler LC480 (Roche) 198 
instrument. 199 
For β-galactosidase activity brains were perfused with PBS, snap frozen and cut at 200 
cryostat. 10 µm sections were fixed for 10 minutes in 0.2 % glutaraldehyde, rinsed and 201 
incubated in X-Gal staining solution according to standard procedure. 202 
Samples from control and Pld3ko mice were lysate in 0.4% Diethylamine, 50 mM NaCl, 50 203 
mM Tris-HCl buffer with EDTA free protease inhibitors and processed for WB or ELISA. WB 204 
densitometry and ELISA were normalized as for cells lysates above. Brains from control and 205 
Pld3ko;Appki mice were perfused in PBS. Next, half brain was postfixed in 4% PFA, rinsed, 206 
cut at 100 µm at the vibratome and processed for thioflavin staining; the other half was 207 
homogenised in tissue protein extraction reagent (Pierce) with protease inhibitors. Extraction 208 
of TBS- and Gu-soluble Aβ was performed as described9. 209 
Thioflavin staining was performed according to standard technique, for confocal imaging 210 
we used Olympus FV1000 IX2 Inverted Confocal microscope with 20x UPlanSapo. Images 211 
were automatically thresholded and quantified with ImageJ. 212 
Colabelling of PLD3 in HEK293 cells with EEA1 and LAMP1 was done with the antibodies 213 
anti-PLD3 (Sigma, #HPA012800; dilution 1/200), anti-EEA1 (BD, #610456; 1/500) and anti-214 
LAMP1 (Santa cruz, #sc-19992; 1/500) according to standard IF techniques. Samples were 215 
fixed in PFA 4% for 10 minutes. Pictures were taken with an Olympus FV1000 IX2 Inverted 216 
Confocal microscope with 60x UPlanSapo. Generation of PDM image and quantification of 217 
Pearson’s and Mander’s coefficients was performed using the ImageJ Plug-in “Intensity 218 
Correlation Analysis”. 219 
For EM analysis, Pld3ko mice and control littermates were perfused at 1 month with 2.5% 220 
glutaraldehyde, 2% paraformaldehyde in 0.1 M cacodylate buffer. 300 µm coronal brain 221 
sections were cut on a vibratome and rectangular pieces of tissue comprising the CA1 222 
region were dissected. Briefly, the tissue was post-fixed with 1% OsO4, 1.5% K4Fe(CN)6 in 223 
0.1 M cacodylate buffer, rinsed, stained with 3% uranyl acetate and dehydrated in graded 224 
ethanols and propyleneoxide, followed by embedding in EMbed812. 70 nm ultrathin sections 225 
were mounted on copper grids and imaged at 3000x using a JEM-1400 transmission 226 
electron microscope (Jeol). 227 
 228 
  229 
Figure legends 230 
Figure 1 231 
a, WB of lysates from control and Pld3ko show APP FL, APP CTF and Pld3 expression in 232 
cortex at 3 months. 233 
b, Densitometry of WB and ELISA quantification Aβ40 and Aβ42 levels in cortex from 234 
Pld3ko mice relative to control mice. n>7 control and n=10 Pld3ko mice. Graphs show mean ± 235 
SEM. 236 
c, WB of lysates from control and Pld3ko;Appki show APP FL, APP CTF and Pld3 237 
expression in cortex at 4 months. 238 
d, Densitometry of WB and ELISA of TBS- Aβ40 and Aβ42. Graphs show mean ± SEM. 239 
n=8 for both Ctrl and Pld3ko;Appki. 240 
Figure 2 241 
a, Confocal images of thioflavin stained cortices from control and Pld3ko;Appki mice. Scale 242 
bar 50 µm. 243 
b, Quantification of amyloid plaques burden as percentage of area occupied by the 244 
plaques. Graphs show mean ± SEM. n=8 for both Ctrl and Pld3ko;Appki. 245 
  246 
Extended Data Figure legends 247 
Extended Data 1 248 
a, Schema of the Pld3 targeted inactivation and LacZ-tagging strategy in Pld3ko mice. The 249 
trapping cassette with a splicing acceptor followed by a IRES:lacZ knocked-in was inserted 250 
between exon 9 and 10. Coloured bars indicate the primer binding sites of qPCRs (shown in 251 
b). SA, splicing acceptor; IRES, internal ribosome entry site; neo, neomycine cassette. 252 
b, Validation of Pld3 inactivation by qPCR. The expression of exons 7-8 is strongly 253 
reduced, while exons 9-10 are not detectable (nd) in Pld3KO mice which express LacZ  254 
instead at 1 month (e9-LacZ). Expression levels are plotted relative to respective reference. 255 
nd, expression value < 0.005. n=6 for Ctrl and Pld3ko mice; Graphs represent the mean ± 256 
SD; ***P<0.001. T test. 257 
c, qPCR expression analysis of mRNA of App and of genes involved in its processing in 258 
Pld3ko relative to control mice at 1 month. n=6 for WT and Pld3ko mice; Graphs represent the 259 
mean ± SD. 260 
d, X-gal staining of Pld3het brain show the expression of Pld3 in neurons at 1 month. Fast 261 
red is used as counterstaining. Cx, cortex; cc, corpus callosum; Hip, hippocampus; so, 262 
stratum oriens; sp, stratum pyramidalis; sr, stratum radiatum; DG, dentate gyrus. Scale bar 263 
500 µm. l’,l’’ and l’’’ show insets from l in sp, so and cc respectively. Scale bar 20 µm. l’, X-264 
gal staining in CA1 pyramidal layer of the hippocampus. l’’, l’’’, β-galactosidase activity is 265 
not detectable in interneurons of the hippocampus (full arrowheads in l’’) nor in the glia cells 266 
of the corpus callosum (empty arrowheads in l’’’).  267 
e,   Dorsal, lateral; and central view of representative brains from control and Pld3ko mice 268 
at 3 months. w, width; l, length; h, height; t, thickness.  269 
f, Morphometric quantification of e. Graphs show mean ± SD. n=2 Ctrl and n=3 Pld3ko 270 
Scale bar 2 mm. 271 
g, Representative WB of lysates from control and Pld3ko show APP FL, APP CTF and 272 
Pld3 expression in hippocampus at 3 months. 273 
h, Densitometric analysis of WB and ELISA quantification Aβ40 and Aβ42 levels in  274 
hippocampus from Pld3ko mice relative to control mice. n>7 control and n=10 Pld3ko mice 275 
from three litters. Graphs show mean ± SEM. 276 
i, ELISA of GU-soluble Aβ40 and Aβ42. Graphs show mean ± SEM. n=8 for both Ctrl and 277 
Pld3ko;Appki; ** P<0.01, two-way ANOVA. 278 
Extended Data 2 279 
a, Enzyme-linked immunosorbent assay (ELISA) shows the levels of Aβ40 and Aβ42 in 280 
the supernatant of HEK293T transfected with TransIT-LT1 to express either GFP as control 281 
or PLD3 WT, PLD3 KR, and PLD3 VM. Aβ levels are expressed relative to control. Graph 282 
shows mean ± SEM. n=6 out of 2 experiments. ***, P<0.001. Two-way ANOVA. 283 
b, Representative WBs show APP FL, APP CTF and PLD3 in lysates from HEK293T 284 
cells from the experiment in q. 285 
c, Densitometric analysis of WBs from the experiment in q,r. Graphs shows mean ± SEM. 286 
n=6 out of 2 experiments. *, P<0.05. Two-way ANOVA. 287 
d, Levels of Aβ40 and Aβ42 in the supernatant of HEK293 cells electroporated with 2.5, 288 
0.75, and 0.25 µgr of PLD3 WT, PLD3 KR, and PLD3 VM relative to GFP electroporated 289 
control cells. Graphs shows mean ± SEM. n=6 out of 3 experiments. *, P<0.05. Two-way 290 
ANOVA. 291 
e, Representative WBs show APP FL, APP CTF and PLD3 in lysates from d. For PLD3 292 
short and long exposures of the same blot are shown. 293 
f, Densitometry of WBs from e. Levels are relative to control. Graphs shows mean ± SEM. 294 
n=6 out of 3 experiments. 295 
Extended Data 3 296 
a, Confocal images show that PLD3 does not colocalize with EEA1 in early endosomes. 297 
The inset shows area magnified in the right panels. Product of the difference of the mean 298 
(PDM) image illustrates the negative correlation of PLD3 and EEA1 (light blue arrowheads). 299 
The right bar shows colour codes for PDM values (negative in blue and positive in orange). 300 
Scale bars 5 µm. 301 
b, Pearson coefficients for EEA1/PLD3 (n=5) and LAMP1/PLD3 (n=7). Graph shows 302 
Means ± SEM. 303 
c, PLD3 is mostly localized in LAMP1 positive late endosomes/lysosomes. The inset 304 
shows area magnified in the right panels. PDM image shows the positive correlation of PLD3 305 
and LAMP1 staining (yellow arrowheads). Scale bars 5 µm. Colour scales indicate PDM 306 
values.  307 
d, Mander’s coefficients for LAMP1 and PLD3 co-labelling. Graph shows Means ± SEM, 308 
n=7. 309 
e, Representative EM pictures of primary and secondary lysosomes (white and black 310 
arrowheads respectively) from control and Pld3 deficient neurons. The arrow indicates 311 
electron-transparent inclusion in a secondary lysosome. Scale bars: 500 nm. 312 
 313 
f, Density, size and area occupied by primary lysosomes. Graph shows Means ± SEM.  314 
For density and area: Ctrl, n = 50 fields out of 2 brains; Pld3ko, n = 84 out of 3 brains. For 315 
density: *p<0.05, Mann Whitney test. For area: ***p<0.001, T test. For size: Ctrl: n=91; 316 
Pld3ko, n=208; ***p<0.001, T test. 317 
 318 
g, Density, size and area occupied by secondary lysosomes. Graph shows Means ± 319 
SEM.  320 
For density and area: Ctrl, n = 50 fields out of two brains; Pld3ko, n = 84 out of 3 brains. 321 
For density: *p<0.05, Mann Whitney test. For area: ***p<0.001, T test. For size: Ctrl: n=22; 322 
Pld3ko, n=73; *p<0.05, T test. 323 
 324 
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